Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO

This article was originally published in PharmAsia News

Executive Summary

BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech

You may also be interested in...



WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

WuXiPharmaTech's biologics manufacturing site is expected to be fully operational in 2012.

WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

WuXiPharmaTech's biologics manufacturing site is expected to be fully operational in 2012.

WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year

Related Content

UsernamePublicRestriction

Register

SC075047

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel